|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inflammatory bowel disease serology in Asia and the West显示文摘AIM:To study serological antibodies in Caucasians and Asians,in health and inflammatory bowel disease(IBD),in Australia and Hong Kong(HK).METHODS:Anti-glycan antibodies[anti-chitobioside(ACCA),anti-laminaribioside(ALCA)],and anti-mannobioside(AMCA),anti-Saccharomyces cervisiae(gASCA);and atypical perinuclear anti-neutrophil cytoplasmic antibody(pANCA)were tested in IBD patients,their unaffected relatives,and healthy controls in Australia and HK(China).Antibody status(positive or negative)and titre was compared between subjects of different geography,ethnicity and disease state.RESULTS:Ninety subjects were evaluated:21 Crohn’s disease(CD),32 ulcerative colitis(UC),29 healthy controls,and 8 IBD patient relatives.Forty eight subjects were Australian(29 Caucasian and 19 ethnic Han Chinese)and 42 were from HK(all Han Chinese).Caucasian CD patients had a significantly higher antibody prevalence of gASCA(67%vs 3%,P<0.001),ALCA(44%vs 6%,P=0.005),and AMCA(67%vs 15%,P=0.002),whereas HK CD patients had a higher prevalence of only AMCA(58%vs 25%,P=0.035),when compared with UC and healthy subjects in both countries.Caucasian CD had significantly higher gASCA prevalence(67%vs 0%,P<0.001)and titre(median59 vs 9,P=0.002)than HK CD patients.Prevalence and titres of ALCA,ACCA and AMCA did not differ between CD in the two countries.Presence of at least one antibody was higher in Caucasian than HK CD patients(100%vs 58%,P=0.045).pANCA did not differ between countries or ethnicity.CONCLUSION:Serologic CD responses differ between HK Asian and Australian Caucasian patients.Different genetic,environmental or disease pathogenic factors may account for these differences. | Lani Prideaux Michael A Kamm Peter De Cruz Daniel R van Langenberg Siew C Ng Iris Dotan | 2013 | World Journal of Gastroenterology2013，19，37： | 10 |
| 2 | Ileal-anal pouches: A review of its history, indications, and complications显示文摘The ileal pouch anal anastomosis(IPAA)has revolutionised the surgical management of ulcerative colitis(UC)and familial adenomatous polyposis(FAP).Despite refinement in surgical technique(s)and patient selection,IPAA can be associated with significant morbidity.As the IPAA celebrated its 40th anniversary in 2018,this review provides a timely outline of its history,indications,and complications.IPAA has undergone significant modification since 1978.For both UC and FAP,IPAA surgery aims to definitively cure disease and prevent malignant degeneration,while providing adequate continence and avoiding a permanent stoma.The majority of patients experience long-term success,but“early”and“late”complications are recognised.Pelvic sepsis is a common early complication with far-reaching consequences of long-term pouch dysfunction,but prompt intervention(either radiological or surgical)reduces the risk of pouch failure.Even in the absence of sepsis,pouch dysfunction is a longterm complication that may have a myriad of causes.Pouchitis is a common cause that remains incompletely understood and difficult to manage at times.10%of patients succumb to the diagnosis of pouch failure,which is traditionally associated with the need for pouch excision.This review provides a timely outline of the history,indications,and complications associated with IPAA.Patient selection remains key,and contraindications exist for this surgery.A structured management plan is vital to the successful management of complications following pouch surgery. | Kheng-Seong Ng Simon Joseph Gonsalves Peter Michael Sagar | 2019 | World Journal of Gastroenterology2019，25，31： | 6 |
| 3 | Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy显示文摘我们与优先的主要雄激素剥夺治疗(ADT ) 在变形前列腺癌症在前进木头(PSAVAP ) 以后调查了前列腺特定的抗原天底(TTPN ) 和前列腺特定的抗原速度的对数的时间的协会。从 2000 ~ 2009 与主要 ADT 对待的所有变形前列腺癌症病人被考察。开发了疾病前进的病人在随后的分析被包括。病人们根据他们的 TTPN 被分成三个组:< 的 TTPN; 3 个月, 3-17 月,和 > 17 个月。我们用 Mann-Whitney U-test 和 Kruskal-Wallis 测试比较了在不同 TTPN 组之间的木头(PSAVAP ) 。木头(PSAVAP ) 上的进一步多重的线性回归分析被执行为使因素惊讶的另外的潜力调整。在与主要 ADT 被对待的 419 个病人之中, 306 个病人与 28 个月的中部的后续开发了疾病前进。更长的 TTPN 与更低的木头(PSAVAP ) 被联系(P = 0.008 ) 在所有亚群分析以内(< 的 TTPN; 3 对 3-17 月, P = 0.020;3-17 对 > 的 TTPN; 17 个月, P = 0.009;并且 < 的 TTPN; 3 对 > 17 个月, P = 0.001 ) 。在多重线性回归分析之上,基线 PSA (回归系数 0.001 , P = 0.045 ), PSA 天底(回归系数 0.002 , P = 0.040 ),并且 TTPN (回归系数 − ; 0.030 , P = 0.001 )是显著地与木头( PSAVAP )被联系的三个因素。在结论,更长的 TTPN 在跟随主要 ADT 的变形前列腺癌症病人与更低的木头(PSAVAP ) 被联系。在 3 个月和 17 个月的 TTPN cut-offs 看起来在预言木头(PSAVAP ) 有预示的意义。TTPN 可以在与疾病前进在病人决定治疗策略用作好预示的指示物。 | Jeremy YC Teoh James HL Tsu Steffi KK Yuen Peter KF Chiu Samson YS Chan Ka-Wing Wong Kwan-Lun Ho Simon SM Hou Chi-Fai Ng Ming-Kwong Yiu | 2017 | Asian Journal of Andrology2017，19，1： | 6 |
| 4 | Inflammatory bowel disease in Asia: A systematic review显示文摘 | Lani Prideaux Michael A Kamm Peter P De Cruz Francis K L Chan Siew C Ng | 2012 | Journal of Gastroenterology and Hepatology2012，，8： | 5 |
| 5 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 6 | Graft Injury in Relation to Graft Size in Right Lobe Live Donor Liver Transplantation: A Study of Hepatic Sinusoidal Injury in Correlation With Portal Hemodynamics and Intragraft Gene Expression显示文摘 | Kwan Man Sheung-Tat Fan Chung-Mau Lo Chi-Leung Liu Peter Chin-Wan Fung Ting-Bo Liang Terence Kin-Wah Lee Steven Hung-Teng Tsui Irene Oi-Lin Ng Zhi-Wei Zhang John Wong | 2003 | Annals of Surgery2003，，2： | 3 |
| 7 | A lysine binding protein in SLE sera inhibits the binding of immune complexes to normal erythrocyte CR (complement receptor type)显示文摘 | Peters D K Cederholm-williams S A | 1987 | Clin Exp Immunol1987，69，： | 1 |
| 8 | A Phase II Trial of Gemcitabine Plus Capecitabine for Metastatic Renal Cell Cancer Previously Treated With Immunotherapy and Targeted Agents显示文摘 | Nizar M. Tannir Peter F. Thall Chaan S. Ng Xuemei Wang Leiko Wooten Arlene Siefker-Radtke Paul Mathew Lance Pagliaro Christopher Wood Eric Jonasch | 2007 | The Journal of Urology2007，，： | 1 |
| 9 | Geographic distribution of vacA allelic types of Helicobacter pylori显示文摘 | Leen–Jan Van Doorn Céu Figueiredo Francis Mégraud Salvador Pena Peter Midolo Dulciene Maria De Magalh?es Queiroz Fátima Carneiro Bart Vanderborght Maria Da Glória F. Pegado Ricardo Sanna Wink De Boer Peter M. Schneeberger Pelayo Correa Enders K.W. Ng John | 1999 | Gastroenterology1999，，4： | 1 |
| 10 | Biogeography of the Indo-Australian Archipelago显示文摘 | David J. Lohman Mark de Bruyn Timothy Page Kristina von Rintelen Robert Hall Peter K.L. Ng Hsi-Te Shih Gary R. Carvalho Thomas von Rintelen | 2011 | Annual Review of Ecology, Evolution, and Systematics2011，，： | 1 |
| 11 | Accuracy of orbscan pachymetry measurements and DGH ultrasound pachymetry in primary laser in situ keratomileusis and Lasik enhancement procedures 显示文摘 | Iskander NG Anderson PE Peters NT | 2001 | J Cataract Refract Surg2001，27，： | 1 |
| 12 | A Knowledge-Based Approach to Effective Document Retrieval 显示文摘 | Fang Sheng Xien Fan Gary Thomas Peter NG | 2001 | Journal of System Integration2001，，10： | 1 |
| 13 | The role of complement and its receptor in the elimination of immune complexes显示文摘 | Schifferli J A NG YG Peters D K | 1986 | N Engl J Med1986，315，8： | 1 |
| 14 | World cities or great cities? A comparative study of five Asian metropolises显示文摘 | Mee Kam Ng Peter Hills | 2003 | Cities2003，，3： | 1 |
| 15 | Partial characterization of a genomic island associated with the multidrug resistance region of Salmonella enterica typhimurium DT104显示文摘 | Boyd DA Peters GA Ng LK | 2000 | FEMS Microbiol Lett2000，189，2： | 1 |
| 16 | C3 nephritic factor (C3NeF): dissociation of cellbound and fluid phase stabilization of alternative pathway C3 eonvertase 显示文摘 | Ng YC Peters DK | 1986 | Clin Exp Immunol1986，65，2： | 1 |
| 17 | Multiphoton-FLIM quantification of the EGFP-mRFP1 FRET pair for localization of membrane receptorkinase interactions显示文摘 | Peter M Ameer-Beg S M Hughes M K Keppler M D Prag S Marsh M Vojnovic B Ng T | | 0，，02： | 1 |
| 18 | Accuracy of Orbscan pachymetry measurements and DHG ultrasound pachymetry in pri- mary laser in situ keratomileusis and LASIK enhancement proce- dures显示文摘 | Iskander NG Anderson PE Peters NT | 2001 | J Cataract Refract Surg2001，27，： | 1 |
| 19 | Accuracy of Orbscan pachymetry measurement and DHG ultrasound pachymetry in primary laser in situ keratomileusis and LASIK enhancement procedures显示文摘 | Iskander NG Anderson Penno E Peters NT | 2001 | J Cataract Refract Surg2001，27，5： | 1 |
| 20 | Accuracy of Orbscan pachymetry measurements and DHG ultrasound pachymetry in primary laser in situ keratomileusis and LASIK enhancement procedures 显示文摘 | Iskander NG Anderson Penno E Peters NT | 2001 | J Cataract Refract Surg2001，27，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员